HYPMY
Hypermarcas S.A.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HYPMY
this stock
Hypermarcas S.A.
|
$2.79B | -3.1% | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.04B | +7.4% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.73B | +4.9% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.76B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- +13.4K sh
- Top holder
- RHUMBLINE ADVISERS
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HYPMY | -3.7% | +0.0% | -8.9% | -3.7% | -3.1% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -3.5% | -0.8% | -16.3% | -3.5% | -12.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.